Moderna, Merck unveil mRNA-based cancer vaccine that cuts spread

What the report says

Moderna and Merck said their personalised mRNA cancer vaccine, Intismeran, reduced melanoma recurrence and the spread of tumours in a late-stage trial, according to results reported by Al Jazeera on 19 August 2026. The companies described the study as meeting its key goals, though they have not yet released the full data. Detailed findings are expected to be presented at an upcoming medical meeting.

The vaccine was tested together with Merck’s immunotherapy drug Keytruda in patients with high-risk melanoma. Moderna said the approach is designed to train the immune system to recognise cancer-linked mutations and attack tumour cells. The companies said they are already discussing the treatment with regulators. Moderna President Stephen Hoge said the vaccine could potentially help thousands of patients whose melanoma has been removed surgically if it wins approval.

The report says this is the first positive late-stage trial result for an mRNA cancer vaccine, which has drawn attention because the same technology was used in some COVID-19 vaccines and is being studied for other cancers, including lung, breast and pancreatic tumours. Al Jazeera also noted that the news lifted Moderna’s shares sharply. More broadly, the result may be significant because solid-tumour cancers have been difficult to treat, and immunotherapy researchers see the finding as an encouraging early step.